HK Stock Market Move | INSILICO (03696) increased by over 10%, the company established the industry's first Longevity Committee, and the Vice President of Lilly Molecular Discovery Group was appointed as the Chairman.

INSILICO (03696) The increase expanded by more than 10%, as of the time of publication, it increased by 9.73%, reaching 75 Hong Kong dollars, with a turnover of 3.18 billion Hong Kong dollars. On the news front, INSILICO announced the establishment of the industry's first Longevity Committee, aiming to provide scientific supervision and strategic guidance for aging research and drug discovery empowered by AI, empowering drug development targeting the underlying biology of aging, and promoting a shift from passive disease care to active healthspan and peak longevity extension. It is reported that the areas of focus of the committee include: life model research, aging biomarker development, identification of dual-purpose targets simultaneously related to aging, longevity, and diseases, as well as clinical development through biomarker and basic model verification of drug effects on key aging features. Dr. Andrew Adams, Vice President of Molecular Discovery Group at Relay Therapeutics, serves as the chairman of the committee, this key role will bridge the critical link between cutting-edge longevity science and large-scale pharmaceutical drug development.